Predictors of clinical progression in HIV-1-infected adults initiating combination antiretroviral therapy with advanced disease in the Asia-Pacific region: Results from the TREAT Asia HIV Observational Database

• Main Authors: H. Byakwaga, K. Petoumenos, J. Ananworanich, F. Zhang, M. A. Boyd, T. Sirisanthana, P. C.K. Li, C. Lee, C. V. Mean, V. Saphonn, S. F.S. Omar, S. Pujari, P. Phanuphak, P. L. Lim, N. Kumarasamy, Y. M.A. Chen, T. P. Merati, S. Sungkanuparph, R. Ditangco, S. Oka, G. Tau, J. Zhou, M. G. Law, S. Emery
• Other Authors: University of New South Wales (UNSW) Australia
• Format: Article
• Published: 2018
• Subjects: Immunology and Microbiology; Medicine
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/31904
• Institution: Mahidol University

The majority of HIV-infected patients in developing countries commences combination antiretroviral therapy (cART) with advanced disease. We examined predictors of disease progression in patients initiating cART with CD4 count ≤200 cells/mm3 in the TREAT Asia HIV Observational Database. The main outcome measure was progression to either an AIDS-defining illness or death occurring 6 months after initiation of cART. We used survival analysis methods. A total of 1255 patients contributed 2696 person years of follow-up; 73 were diagnosed with AIDS and 9 died. The rate of progression to the combined end point was 3.0 per 100 person years. The factors significantly associated with a higher risk of disease progression were Indian ethnicity, infection through intravenous drug use, lower CD4 count, and hemoglobin ≤130 g/dL at 6 months. In conclusion, measurements of CD4 count and hemoglobin at month 6 may be useful for early identification of disease progression in resource-limited settings. © The Author(s) 2012.